{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:57:15Z","timestamp":1791835035373,"version":"4.3.4"},"reference-count":73,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pentecost Myeloma Research Center"},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U54CA193489-01A1"],"award-info":[{"award-number":["1U54CA193489-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA195727"],"award-info":[{"award-number":["1R01CA195727"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow\u2013resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. In this study, we present an integrated functional genomic analysis of tumor samples from patients multiple myeloma that were assessed for their ex vivo drug sensitivity to 37 drugs, clinical variables, cytogenetics, mutational profiles, and transcriptomes. This analysis revealed a multiple myeloma transcriptomic topology that generates \u201cfootprints\u201d in association with ex vivo drug sensitivity that have both predictive and mechanistic applications. Validation of the transcriptomic footprints for the anti-CD38 mAb daratumumab (DARA) and the nuclear export inhibitor selinexor (SELI) demonstrated that these footprints can accurately classify clinical responses. The analysis further revealed that DARA and SELI have anticorrelated mechanisms of resistance, and treatment with a SELI-based regimen immediately after a DARA-containing regimen was associated with improved survival in three independent clinical trials, supporting an evolutionary-based strategy involving sequential therapy. These findings suggest that this unique repository and computational framework can be leveraged to inform underlying biology and to identify therapeutic strategies to improve treatment of multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Functional genomic analysis of primary multiple myeloma samples elucidated predictive biomarkers for drugs and molecular pathways mediating therapeutic response, which revealed a rationale for sequential therapy to maximize patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-24-0886","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:56:13Z","timestamp":1730296573000},"page":"378-398","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma"],"prefix":"10.1158","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-9332","authenticated-orcid":false,"given":"Praneeth Reddy","family":"Sudalagunta","sequence":"first","affiliation":[{"name":"1Department of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-8512","authenticated-orcid":false,"given":"Rafael R.","family":"Canevarolo","sequence":"additional","affiliation":[{"name":"1Department of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0259-1875","authenticated-orcid":false,"given":"Mark B.","family":"Meads","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6787-6695","authenticated-orcid":false,"given":"Maria","family":"Silva","sequence":"additional","affiliation":[{"name":"1Department of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-7426","authenticated-orcid":false,"given":"Xiaohong","family":"Zhao","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-7451","authenticated-orcid":false,"given":"Christopher L.","family":"Cubitt","sequence":"additional","affiliation":[{"name":"3Cancer Pharmacokinetics and Pharmacodynamics Core, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-7149","authenticated-orcid":false,"given":"Samer S.","family":"Sansil","sequence":"additional","affiliation":[{"name":"3Cancer Pharmacokinetics and Pharmacodynamics Core, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3826-862X","authenticated-orcid":false,"given":"Gabriel","family":"DeAvila","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-1204","authenticated-orcid":false,"given":"Raghunandan Reddy","family":"Alugubelli","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-4798","authenticated-orcid":false,"given":"Ryan T.","family":"Bishop","sequence":"additional","affiliation":[{"name":"4Department of Tumor Microenvironment and Metastasis, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9851-1324","authenticated-orcid":false,"given":"Alexandre","family":"Tungesvik","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, University of South Florida, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1484-4304","authenticated-orcid":false,"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"6Aster Insights (formerly M2Gen), Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9164-1070","authenticated-orcid":false,"given":"Oliver","family":"Hampton","sequence":"additional","affiliation":[{"name":"6Aster Insights (formerly M2Gen), Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-0282","authenticated-orcid":false,"given":"Jamie K.","family":"Teer","sequence":"additional","affiliation":[{"name":"7Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-3855","authenticated-orcid":false,"given":"Eric A.","family":"Welsh","sequence":"additional","affiliation":[{"name":"7Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-3279","authenticated-orcid":false,"given":"Sean J.","family":"Yoder","sequence":"additional","affiliation":[{"name":"8Molecular Genomics Core, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7040-4084","authenticated-orcid":false,"given":"Lori","family":"Hazlehurst","sequence":"additional","affiliation":[{"name":"9Department of Pharmaceutical Sciences, West Virginia University, Morgantown, West Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1621-1510","authenticated-orcid":false,"given":"Robert A.","family":"Gatenby","sequence":"additional","affiliation":[{"name":"10Department of Radiology, Moffitt Cancer Center and Research Institute, Tampa, Florida."},{"name":"11Department of Integrated Mathematical Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0051-7790","authenticated-orcid":false,"given":"Dane R.","family":"Van Domelen","sequence":"additional","affiliation":[{"name":"12Research and Translational Development, Karyopharm Therapeutics, Newton, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-587X","authenticated-orcid":false,"given":"Yi","family":"Chai","sequence":"additional","affiliation":[{"name":"12Research and Translational Development, Karyopharm Therapeutics, Newton, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-7978","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"12Research and Translational Development, Karyopharm Therapeutics, Newton, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5248-4843","authenticated-orcid":false,"given":"Andrew","family":"DeCastro","sequence":"additional","affiliation":[{"name":"12Research and Translational Development, Karyopharm Therapeutics, Newton, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2737-8631","authenticated-orcid":false,"given":"Amanda M.","family":"Bloomer","sequence":"additional","affiliation":[{"name":"13Total Cancer Care, Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1779-2510","authenticated-orcid":false,"given":"Erin M.","family":"Siegel","sequence":"additional","affiliation":[{"name":"13Total Cancer Care, Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-6244","authenticated-orcid":false,"given":"Conor C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"4Department of Tumor Microenvironment and Metastasis, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0951-9781","authenticated-orcid":false,"given":"Daniel M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4946-823X","authenticated-orcid":false,"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"14Department of Blood and Marrow Transplant and Cellular Therapies, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"14Department of Blood and Marrow Transplant and Cellular Therapies, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-2279","authenticated-orcid":false,"given":"Jason","family":"Brayer","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9065","authenticated-orcid":false,"given":"John L.","family":"Cleveland","sequence":"additional","affiliation":[{"name":"4Department of Tumor Microenvironment and Metastasis, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-0454","authenticated-orcid":false,"given":"William","family":"Dalton","sequence":"additional","affiliation":[{"name":"15Molecular Medicine Program, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-4777","authenticated-orcid":false,"given":"Christopher J.","family":"Walker","sequence":"additional","affiliation":[{"name":"12Research and Translational Development, Karyopharm Therapeutics, Newton, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5085-6263","authenticated-orcid":false,"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[{"name":"12Research and Translational Development, Karyopharm Therapeutics, Newton, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-9986","authenticated-orcid":false,"given":"Ariosto S.","family":"Silva","sequence":"additional","affiliation":[{"name":"1Department of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2026042309465312700_bib1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/ajhp\/zxac091","article-title":"New and emerging pharmacotherapies for management of multiple myeloma","volume":"79","author":"Moore","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"2026042309465312700_bib2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.exphem.2015.04.010","article-title":"Novel therapeutic strategies for multiple myeloma","volume":"43","author":"Mimura","year":"2015","journal-title":"Exp Hematol"},{"key":"2026042309465312700_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026042309465312700_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026042309465312700_bib5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2026042309465312700_bib6","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1002\/cpmb.59","article-title":"Overview of next-generation sequencing technologies","volume":"122","author":"Slatko","year":"2018","journal-title":"Curr Protoc Mol Biol"},{"key":"2026042309465312700_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neo.2021.02.002","article-title":"Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"Wang","year":"2021","journal-title":"Neoplasia"},{"key":"2026042309465312700_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/EDBK_175175","article-title":"Established and novel prognostic biomarkers in multiple myeloma","volume":"37","author":"Bustoros","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026042309465312700_bib9","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-17-0502","article-title":"An ex vivo platform for the prediction of clinical response in multiple myeloma","volume":"77","author":"Silva","year":"2017","journal-title":"Cancer Res"},{"key":"2026042309465312700_bib10","doi-asserted-by":"crossref","first-page":"102716","DOI":"10.1016\/j.ebiom.2020.102716","article-title":"A pharmacodynamic model of clinical synergy in multiple myeloma","volume":"54","author":"Sudalagunta","year":"2020","journal-title":"EBioMedicine"},{"key":"2026042309465312700_bib11","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"key":"2026042309465312700_bib12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/JLB.5A0220-676RR","article-title":"Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia","volume":"107","author":"Lin","year":"2020","journal-title":"J Leukoc Biol"},{"key":"2026042309465312700_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"2026042309465312700_bib14","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/blood.V126.23.4219.4219","article-title":"Safety and efficacy of venetoclax (ABT-199\/GDC-0199) monotherapy for relapsed\/refractory multiple myeloma: phase 1 preliminary results","volume":"126","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"2026042309465312700_bib15","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"Suppl 15","key":"2026042309465312700_bib16","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1200\/JCO.2020.38.15_suppl.8530","article-title":"Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed\/refractory multiple myeloma (MM)","volume":"38","author":"Gasparetto","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026042309465312700_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jha2.122","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"2","author":"Gasparetto","year":"2021","journal-title":"EJHaem"},{"issue":"Suppl 1","key":"2026042309465312700_bib18","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2021-149701","article-title":"Single cell RNA sequencing in patients enrolled in a selinexor clinical trial reveals overexpression of alternative nuclear export pathways associated with resistance to selinexor in refractory multiple myeloma","volume":"138","author":"Cohen","year":"2021","journal-title":"Blood"},{"key":"2026042309465312700_bib19","first-page":"e53070","article-title":"An organotypic high throughput system for characterization of drug sensitivity of primary multiple myeloma cells","volume":"15","author":"Silva","year":"2015","journal-title":"J Vis Exp"},{"key":"2026042309465312700_bib20","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/s41467-024-46594-0","article-title":"The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease","volume":"15","author":"Bishop","year":"2024","journal-title":"Nat Commun"},{"key":"2026042309465312700_bib21","first-page":"2579","article-title":"Visualizing data using t-SNE","volume":"9","author":"van der Maaten","year":"2008","journal-title":"J Mach Learn Res"},{"key":"2026042309465312700_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0098-3004(84)90020-7","article-title":"FCM: the fuzzy c-means clustering algorithm","volume":"10","author":"Bezdek","year":"1984","journal-title":"Comput Geosci"},{"key":"2026042309465312700_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2026042309465312700_bib24","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41375-019-0689-0","article-title":"Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma","volume":"34","author":"Maura","year":"2020","journal-title":"Leukemia"},{"key":"2026042309465312700_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood.2023020276","article-title":"Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency","volume":"143","author":"Leblay","year":"2024","journal-title":"Blood"},{"key":"2026042309465312700_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2026042309465312700_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-Dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026042309465312700_bib28","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"key":"2026042309465312700_bib29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","article-title":"t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome","volume":"37","author":"An","year":"2013","journal-title":"Leuk Res"},{"key":"2026042309465312700_bib30","doi-asserted-by":"crossref","first-page":"e1134","DOI":"10.1038\/cddis.2014.98","article-title":"Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton","volume":"5","author":"Mithraprabhu","year":"2014","journal-title":"Cell Death Dis"},{"key":"2026042309465312700_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1541-7786.MCR-10-0131","article-title":"PRDM1 is required for mantle cell lymphoma response to bortezomib","volume":"8","author":"Desai","year":"2010","journal-title":"Mol Cancer Res"},{"key":"2026042309465312700_bib32","first-page":"606","article-title":"CYLD in hematological malignancies","volume":"6","author":"Zhou","year":"2021","journal-title":"Ann Case Rep"},{"key":"2026042309465312700_bib33","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1093\/bioinformatics\/btm369","article-title":"GSEA-P: a desktop application for gene set enrichment analysis","volume":"23","author":"Subramanian","year":"2007","journal-title":"Bioinformatics"},{"key":"2026042309465312700_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2026042309465312700_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0303-2647(98)00017-3","article-title":"Computation with the KEGG pathway database","volume":"47","author":"Ogata","year":"1998","journal-title":"Biosystems"},{"key":"2026042309465312700_bib36","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2026042309465312700_bib37","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-08-2419","article-title":"Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation","volume":"69","author":"Shain","year":"2009","journal-title":"Cancer Res"},{"key":"2026042309465312700_bib38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2026042309465312700_bib39","first-page":"7900","article-title":"Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model","volume":"63","author":"Hazlehurst","year":"2003","journal-title":"Cancer Res"},{"key":"2026042309465312700_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"2026042309465312700_bib41","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"key":"2026042309465312700_bib42","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.2022015909","article-title":"Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma","volume":"140","author":"Gooding","year":"2022","journal-title":"Blood"},{"key":"2026042309465312700_bib43","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/blood.2021014391","article-title":"Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma","volume":"139","author":"Trasanidis","year":"2022","journal-title":"Blood"},{"key":"2026042309465312700_bib44","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/bjc.2012.424","article-title":"The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma","volume":"107","author":"Dibb","year":"2012","journal-title":"Br J Cancer"},{"key":"2026042309465312700_bib45","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/ncb1767","article-title":"Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression","volume":"10","author":"Fu","year":"2008","journal-title":"Nat Cell Biol"},{"key":"2026042309465312700_bib46","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1021\/acsmedchemlett.5b00084","article-title":"BRD4 structure-activity relationships of dual PLK1 kinase\/BRD4 bromodomain inhibitor BI-2536","volume":"6","author":"Chen","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"2026042309465312700_bib47","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","article-title":"Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells","volume":"6","author":"Markovina","year":"2008","journal-title":"Mol Cancer Res"},{"key":"2026042309465312700_bib48","doi-asserted-by":"crossref","first-page":"20621","DOI":"10.18632\/oncotarget.4139","article-title":"Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2\u2014implications for a combinatorial treatment","volume":"6","author":"Duvefelt","year":"2015","journal-title":"Oncotarget"},{"key":"2026042309465312700_bib49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/JIR.S279249","article-title":"Crm1-dependent nuclear export of Bach1 is involved in the protective effect of hyperoside on oxidative damage in hepatocytes and CCl4-induced acute liver injury","volume":"14","author":"Cai","year":"2021","journal-title":"J Inflamm Res"},{"key":"2026042309465312700_bib50","doi-asserted-by":"crossref","first-page":"101032","DOI":"10.1016\/j.jbc.2021.101032","article-title":"The transcription factor BACH1 at the crossroads of cancer biology: from epithelial\u2013mesenchymal transition to ferroptosis","volume":"297","author":"Igarashi","year":"2021","journal-title":"J Biol Chem"},{"key":"2026042309465312700_bib51","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1002\/jcb.27168","article-title":"Silencing forkhead box M1 promotes apoptosis and autophagy through SIRT7\/mTOR\/IGF2 pathway in gastric cancer cells","volume":"119","author":"Yu","year":"2018","journal-title":"J Cell Biochem"},{"key":"2026042309465312700_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.canlet.2019.11.014","article-title":"FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK\/mTOR-mediated autophagy","volume":"469","author":"Lin","year":"2020","journal-title":"Cancer Lett"},{"key":"2026042309465312700_bib53","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.3390\/ijms22115955","article-title":"Inactivation of the Akt\/FOXM1 signaling pathway by panobinostat suppresses the proliferation and metastasis of gastric cancer cells","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026042309465312700_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2011.08.016","article-title":"FoxM1 promotes \u03b2-catenin nuclear localization and controls wnt target-gene expression and glioma tumorigenesis","volume":"20","author":"Zhang","year":"2011","journal-title":"Cancer Cell"},{"key":"2026042309465312700_bib55","first-page":"5871","article-title":"Anthelmintic pyrvinium pamoate blocks Wnt\/\u03b2-catenin and induces apoptosis in multiple myeloma cells","volume":"15","author":"Xu","year":"2018","journal-title":"Oncol Lett"},{"key":"2026042309465312700_bib56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5732\/cjc.012.10277","article-title":"Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance","volume":"32","author":"Gomes","year":"2013","journal-title":"Chin J Cancer"},{"key":"2026042309465312700_bib57","doi-asserted-by":"crossref","first-page":"87543","DOI":"10.18632\/oncotarget.13896","article-title":"Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2026042309465312700_bib58","doi-asserted-by":"crossref","first-page":"e31761","DOI":"10.1371\/journal.pone.0031761","article-title":"Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage","volume":"7","author":"Halasi","year":"2012","journal-title":"PLoS One"},{"key":"2026042309465312700_bib59","doi-asserted-by":"crossref","first-page":"696532","DOI":"10.3389\/fonc.2021.696532","article-title":"FOXM1-AKT positive regulation loop provides venetoclax resistance in AML","volume":"11","author":"Chesnokov","year":"2021","journal-title":"Front Oncol"},{"key":"2026042309465312700_bib60","doi-asserted-by":"crossref","first-page":"101162","DOI":"10.1016\/j.jbc.2021.101162","article-title":"TGF-\u03b2\/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters","volume":"297","author":"Webb","year":"2021","journal-title":"J Biol Chem"},{"key":"2026042309465312700_bib61","doi-asserted-by":"crossref","first-page":"9052","DOI":"10.1002\/jcp.27583","article-title":"Foxm1 is a critical driver of TGF-\u03b2-induced EndMT in endothelial cells through Smad2\/3 and binds to the Snail promoter","volume":"234","author":"Song","year":"2019","journal-title":"J Cell Physiol"},{"key":"2026042309465312700_bib62","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1186\/s12885-018-5015-0","article-title":"Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma","volume":"18","author":"Gu","year":"2018","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"2026042309465312700_bib63","first-page":"1261","article-title":"FOXM1 is associated with development of therapeutic resistance in multiple myeloma","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"key":"2026042309465312700_bib64","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1038\/s41467-021-25553-z","article-title":"Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"2026042309465312700_bib65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13046-019-1197-9","article-title":"Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors","volume":"38","author":"Mancini","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2026042309465312700_bib66","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"2026042309465312700_bib67","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41587-022-01379-y","article-title":"A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs","volume":"40","author":"Tatarova","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2026042309465312700_bib68","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1080\/15384047.2015.1095406","article-title":"Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo","volume":"16","author":"Qi","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"2026042309465312700_bib69","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3390\/cancers12082182","article-title":"Simultaneously inhibiting BCL2 and MCL1 is a therapeutic option for patients with advanced melanoma","volume":"12","author":"Mukherjee","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"2026042309465312700_bib70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood-2019-126094","article-title":"T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"2026042309465312700_bib71","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1158\/0008-5472.CAN-09-1354","article-title":"Lessons from applied ecology: cancer control using an evolutionary double bind","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"key":"2026042309465312700_bib72","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"2026042309465312700_bib73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-24-0886\/3513690\/can-24-0886.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/2\/378\/3532350\/can-24-0886.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/2\/378\/3532350\/can-24-0886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:47:11Z","timestamp":1776952031000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/85\/2\/378\/750990\/The-Functional-Transcriptomic-Landscape-Informs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-24-0886","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.7627215","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.28210638","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}